Latest Breaking News On - Prior platinum treatment - Page 1 : comparemela.com

Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on.

United statesNew yorkSan diegoKimberly blackwellMark lacknerProgram updatesExchange commissionZentalis pharmaceuticals incTranslational sciencesGlobenewswire incGenentech oncology early stage biomarker groupDevelopment expensesPharmaceuticals incAmerican association for cancer researchZentalis pharmaceuticalsTranslational officer